What Cherry Biotech does

Cherry Biotech is a French biomedical technology company founded in 2015 and headquartered in Montreuil (Paris), organized as a Société par actions simplifi\u00e9e (SAS). It develops instruments and consumables for drug discovery and personalized medicine, with a stated mission to replace animal testing by combining microfluidic organ-on-chip technology, multi-omics, advanced live-cell imaging, and AI-driven analysis. The company has approximately 16 employees across 11 nationalities, supported by a leadership team that includes Co-Founder and CSO Dr. Thomas Gu\u00e9rinier and R&D lead Dr. Pierre Gaudriault.

The company's core product is the CubiX Platform, a scalable and customizable microenvironment controller fully compatible with live imaging, enabling organoid culture of up to 8 cell types for more than 28 days with a vascularized interface, resident and circulating immunity, and simultaneous control of temperature, medium flow, O2, N2, and CO2. CubiX is currently in pre-sales. Building on CubiX, Cherry Biotech sells the OrganoidPlate consumable family (AdipoPlate for adipose tissue, HepatoPlate for liver co-culture, and CanceroPlate variants for breast and lung cancer) and SmartSphero Plates (microstructured hydrogels for standardized spheroid formation in a "Pipet & Go" workflow). The CherryTemp instrument provides ultra-fast temperature shifts in the 5\u201345\u00b0C range for live-cell imaging, with application packs for phase separation, C. elegans, and yeast studies. Specialized organ models (Adipose Tissue, Breast Cancer, Human Endothelialized Skin-on-Chip) run on the CubiX platform, and the company offers a 3D In Vitro Contract Research Organization (CRO) service for drug developers needing rapid access to organoid technology without capital investment in equipment.

Cherry Biotech serves pharmaceutical companies (Novo Nordisk, Sanofi), biotech firms, academic and translational research institutions (Gustave Roussy, Amsterdam UMC, Vrije Universiteit Brussel, Bielefeld University, CRG, IDIBAPS, CSIC), and CROs/CDMOs. Revenue streams include quote-based hardware and consumable sales, CRO services, and substantial non-dilutive EU public funding (H2020, EIC Transition 2022 / Project I.D.E.F.I.X, EIC Accelerator 2024 / Project ASTEROID, BPI France I-Lab / HOMO CHIPIEN, Eurostars / I-Bracelet, Euronanomed3 / Nano4Stroke, R\u00e9gion Bretagne / CHERRY360 and SpOC). Distribution is direct and consultative via a "Speak with our expert" contact form, supplemented by EU-funded scientific collaborations that serve as co-development channels and the December 2025 Atelerix partnership that enables non-cryogenic global shipping of organoid models. Pricing is not publicly disclosed across any product or service line.

Name

Cherry Biotech

Legal name

Cherry Biotech (Société par actions simplifiée)

Website

https://cherrybiotech.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Cherry Biotech is a French biomedical technology company that develops organ-on-chip platforms (CubiX), ready-to-use organoid consumables (OrganoidPlate family, SmartSphero Plates), and 3D in vitro CRO services to deliver human-relevant preclinical drug testing for pharmaceutical companies, biotech firms, cancer centers, and academic research institutions as an alternative to animal testing.

Ownership category

akta.pro rank

Product category

Organ-on-Chip Instruments

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)

akta.pro secondary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

Keywords

• Organ-on-chip technology
• 3D cell culture
• Microfluidic instruments
• Organoid models
• Preclinical drug testing

Headquarters

HQ city

Montreuil

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. 3D In Vitro Contract Research Organization (CRO) Services: Standard and customized in vitro studies provided as a service to screen new therapeutic candidates, explore mechanisms of action, and accelerate clinical trial design. Particularly suitable for drug developers requiring rapid access to organoids and 3D cell-culture technology without investing in their own equipment. Includes a dedicated service menu.
2. Hardware & Consumable Product Sales (CubiX, CherryTemp, OrganoidPlate, SmartSphero Plates): Direct sales of proprietary hardware platforms (CubiX microenvironment controller, CherryTemp temperature shift device) and consumable plate products (OrganoidPlate ready-to-use organoids including AdipoPlate, HepatoPlate, CanceroPlate lines; SmartSphero Plates microstructured hydrogels). CubiX is in pre-sales phase.
3. EU & French Public Research Grants: Funding from European Union programs (H2020, EIC Accelerator 2024, EIC Transition 2022, EIC Pathfinder) and French programs (BPI France I-Lab, Région Bretagne, Eurostars, Euronanomed3). White paper on animal testing was funded by EU under grant agreement n° 101046928 & 101046928.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels9 records

Core offering

Cherry Biotech develops and sells the CubiX Platform, a microfluidic microenvironment controller fully compatible with live imaging that enables organoid culture of up to 8 cell types for more than 28 days with a vascularized interface, controlling temperature, gas (N2, CO2, O2), and medium flow without an incubator. The company sells ready-to-use organoid consumables (OrganoidPlate family including AdipoPlate, HepatoPlate, CanceroPlate Breast and Lung lines), SmartSphero Plates for standardized spheroid formation, and the CherryTemp ultra-fast temperature-shift device. It also offers 3D In Vitro Contract Research Organization (CRO) services for drug developers needing organoid and 3D cell-culture access without purchasing equipment.

Product overview

Cherry Biotech operates a platform-plus-modules architecture centered on 3D cell culture and organ-on-chip technology. The CubiX Platform is the core instrument: a customizable microenvironment controller compatible with live imaging that allows organoid culture of up to 8 cell types for more than 28 days with a vascularized interface, controlling temperature, medium flow, O2, N2 and CO2. Building on CubiX, the company sells ready-to-use consumable products: the OrganoidPlate family (with sub-products AdipoPlate for adipose tissue, HepatoPlate for liver, and CanceroPlate for breast and lung cancer) and SmartSphero Plates for standardized spheroid formation. The CherryTemp instrument provides ultra-fast temperature shifts in the 5–45°C range for live-cell imaging, with application packs for phase separation, C. elegans, and yeast. Specialized organ models (Adipose Tissue, Breast Cancer, Human Endothelialized Skin-on-Chip) run on CubiX. Alongside products, Cherry Biotech offers a 3D In Vitro CRO service for drug developers who need rapid access to organoid/3D cell-culture technology without purchasing equipment. The whole offering is positioned to replace animal testing by combining microfluidic organ-on-chip, multi-omics, advanced imaging, and AI-driven analysis.

Differentiator

Problem solved

Functional benefit

Brands

• CubiX: Microenvironment controller platform for organoids and live cell imaging; flagship product of the company.
• CherryTemp
• OrganoidPlate
• SmartSphero Plate

Products and services

• CubiX Platform Scalable, highly customizable, user-friendly microenvironment controller fully compatible with live imaging, enabling mimicking of physiological and pathological culture conditions in vitro. Allows organoid culture of up to 8 cell types for more than 28 days with a vascularized interface, resident and circulating immunity, and provides simultaneous user control over temperature, medium flow, O2, N2, and CO2 without an incubator. Target customers are pharma, biotech, and academic research institutions.
• OrganoidPlate Assay-ready, mature and differentiated organoid plates that allow researchers to skip culture time and directly perform assays, providing ready-to-use 3D in vitro organoid models for pre-clinical drug testing. Includes AdipoPlate (adipose tissue), HepatoPlate (liver co-culture), CanceroPlate Breast, and CanceroPlate Lung variants.
• SmartSphero Plates Microstructured hydrogel plates designed for simple, standardized, and consistent spheroid formation. The hydrogel shape provides a microenvironment that enables cells to sediment and self-aggregate within hours, supporting a Pipet & Go organoid culture workflow.
• CherryTemp Ultra-fast temperature-shift device for live-cell imaging, operating in the 5-45°C range. Includes dedicated application packs (Phase Separation Pack, C. Elegans Pack, Yeast Pack) for specific research use cases.
• 3D In Vitro CRO Service Contract research organization service providing both standard and customized in vitro studies to screen therapeutic candidates, explore mechanisms of action, and accelerate clinical trial design. Particularly suitable for drug developers needing rapid access to organoids and 3D cell-culture technology without investing in their own equipment.

Quantifiable outcome

• Global organ-on-chip market projected to grow from USD 134.9 million (2023) to USD 1,424.0 million by 2031 at 34.7% CAGR, with liver-on-a-chip holding the largest market share.
• +3 more outcomes

Named customers7 records

Segments8 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability6 records

Feature7 records

Partnerships

Twelve partnerships are on record, tiered flagship / high-priority commercial partnership, core scientific collaboration partner, technology / equipment ecosystem partner, industry partner, technology / industry partner, industry / cluster partner, ecosystem / cluster partner, marketing / advertising partners, infrastructure / hosting partner and compliance / consulting partner.

• Atelerixflagship / high-priority commercial partnershipStrategic or Co-development Partner · 14 December 2025Atelerix (UK biotech) and Cherry Biotech (France) announced a partnership to develop a non-cryogenic shipping technology for biological materials, specifically organoids. The collaboration aims to enable extended transport at ambient or controlled temperatures, reducing reliance on cold-chain logistics and improving global distribution capabilities. The initial 12-month trial will validate the technology's performance for potential commercial deployment. This agreement integrates Atelerix's non-cryogenic transport solutions with Cherry Biotech's advanced organoid models, facilitating global distribution without cold-chain logistics.
• Institut de Génétique et Développement de Rennes (IGDR)core scientific collaboration partnerStrategic or Co-development Partner · 1 January 2017Co-coordinator of the SpOC (Spheroid On Chip) project (Région Bretagne transfert de technologies, 2017-2018). Cherry Biotech designed the microfluidic device and, in collaboration with IGDR's Y.Arlot team, applied it to drug development, particularly in the lead identification phase. The project aimed to cultivate kidney cancer cells spheroids for at least 5 days in a microfluidic device. Listed as a trusted partner in the homepage "They Trust Us" logo block.
• Elveflowtechnology / equipment ecosystem partnerTechnology or IntegrationListed as a trusted partner in the homepage "They Trust Us" logo block. Elveflow is a provider of microfluidic flow control systems and instruments, indicating a technology ecosystem relationship with Cherry Biotech's organ-on-chip platforms.
• Inside Therapeuticsindustry partnerStrategic or Co-development PartnerListed as a trusted partner in the homepage "They Trust Us" logo block as "Inside-Therapeutics-Lipid-nanoparticle-manufacturing-partner", indicating a collaboration around lipid nanoparticle manufacturing relevant to Cherry Biotech's drug delivery and organoid applications.
• Quimivitaindustry partnerStrategic or Co-development PartnerListed as a trusted partner in the homepage "They Trust Us" logo block.
• 4Dcelltechnology / industry partnerTechnology or IntegrationListed as a trusted partner in the homepage "They Trust Us" logo block. 4Dcell is a technology partner in the cell-based assay and microfluidic space, relevant to Cherry Biotech's organ-on-chip platforms.
• Biosensetechnology / industry partnerTechnology or IntegrationListed as a trusted partner in the homepage "They Trust Us" logo block.
• Groupe ICAREindustry / cluster partnerStrategic or Co-development PartnerListed as a trusted partner in the homepage "They Trust Us" logo block.
• Paris-Saclay Cancer Cluster (PSCC)ecosystem / cluster partnerGTM or Marketing PartnerListed as a trusted partner in the homepage "They Trust Us" logo block (logo_PSCC.png). Paris-Saclay Cancer Cluster is a major oncology innovation cluster in France, providing GTM and ecosystem support relevant to Cherry Biotech's cancer organoid and CubiX applications.
• Google, LinkedIn, Meta (Facebook)marketing / advertising partnersGTM or Marketing PartnerCherry Biotech uses Google Ads, LinkedIn Ads, and Facebook Pixel for advertising and retargeting per its Cookie Policy. These are marketing technology partners enabling paid acquisition.
• OVHinfrastructure / hosting partnerTechnology or IntegrationOVH is the hosting provider (Hébergeur) for the www.cherrybiotech.com website. OVH SAS, capital 10,000,000 €, RCS Roubaix – Tourcoing 424 761 419 00045. Cherry Biotech's data is hosted on European soil.
• Dipeeocompliance / consulting partnerImplementation/ SI/ Consulting PartnerPrivacy Policy is "Certified compliant by Dipeeo®" - Dipeeo is a Data Protection Officer (DPO) consultancy, serving as Cherry Biotech's outsourced independent Data Protection Officer.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Emulate: Emulate is the leading organ-on-chip company (Liver-Chip, Lung-Chip, etc.) and the most direct competitor to Cherry Biotech's CubiX platform, serving pharma R&D with similar in vitro microfluidic models for preclinical drug testing.
• CN Bio Innovations: CN Bio develops organ-on-chip platforms (PhysioMimix) targeting pharma and academic customers for liver, lung, and gut models — overlapping head-to-head with CubiX's positioning in drug discovery and NAMs.
• MIMETAS: MIMETAS provides organ-on-chip technology (OrganoPlate) and disease models for pharma and biotech preclinical research, directly comparable to Cherry Biotech's microfluidic organoid and CubiX offerings.
• TissUse: TissUse builds multi-organ-chip and single-organ-chip systems for drug development and cosmetics testing, directly competing in the same organ-on-chip and animal-replacement space as Cherry Biotech.
• InSphero: InSphero offers 3D microtissue and organoid solutions (liver, pancreatic islets, tumor spheroids) for drug discovery, comparable to Cherry Biotech's OrganoidPlate and SmartSphero Plate consumable products.
• Kirkstall: Kirkstall develops organ-on-chip and 3D cell culture systems (Quasi Vivo) for in vitro toxicology and drug testing, an adjacent organ-on-chip peer with similar pharma and cosmetics customer targets.

Emerging players

• Organovo: Organovo is a 3D biology and bioprinting company developing tissue models for preclinical research; its 3D tissue work overlaps thematically with Cherry Biotech's organoid and CubiX organ-model strategy.
• CytoSMART: CytoSMART provides live-cell imaging and image-analysis solutions, overlapping with Cherry Biotech's live-imaging and AI-driven organoid analysis capabilities on the CubiX platform.

Broad incumbents

• Molecular Devices: Molecular Devices (Danaher) is a large life-sciences instrumentation incumbent supplying live-cell imaging and screening platforms that overlap with Cherry Biotech's imaging and 3D cell-culture workflow.
• Sartorius: Sartorius is a global bioprocessing and lab-tools incumbent with cell-culture and lab-instrumentation products that serve many of the same pharma/biotech customers Cherry Biotech targets with CubiX and CRO services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutu.be/JdvrLzEXyew
• Xx.com/CherryBiotech

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cherry Biotech